Sodium –glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials
ConclusionSGLT2i as an add-on therapy to insulin improved glycemic control and body weight and decreased the required dose of insulin without increasing the risk of hypoglycemia. However, after 6 months the benefits of SGLT2is on glycemic control may weaken and the risks of GTIs and DKA increased.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
More News: Clinical Trials | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Insulin | Sodium | Study | Urinary Tract Infections